化学诱导肿瘤的免疫保护性MHC II表位在一种核糖体蛋白中存在独特突变。
The immunoprotective MHC II epitope of a chemically induced tumor harbors a unique mutation in a ribosomal protein.
作者信息
Matsutake T, Srivastava P K
机构信息
Center for Immunotherapy of Cancer and Infectious Diseases, University of Connecticut School of Medicine, Farmington, CT 06030-1601, USA.
出版信息
Proc Natl Acad Sci U S A. 2001 Mar 27;98(7):3992-7. doi: 10.1073/pnas.071523398.
Abstract
CD4(+) T lymphocyte clones, generated from mice immunized with the methylcholanthrene-induced fibrosarcoma Meth A (H-2(d)), are restricted by I-E(d) and recognize a unique antigen on Meth A. The antigen has been purified and characterized as the ribosomal protein L11. The antigenic epitope is contained within the sequence EYELRKHNFSDTG and is generated by substitution of Asn by His (italic) caused by a single point mutation. The tumor contains the wild-type and the mutated alleles. Immunization of BALB/cJ mice with the mutated epitope but not with the wild-type epitope protects mice against a subsequent challenge with the Meth A sarcoma. Adoptive transfer of CD4(+) clones into BALB/c mice renders the mice specifically resistant to Meth A sarcoma. The mutated L11 epitope is thus shown to be an immunoprotective epitope in vivo by several criteria.
摘要
用甲基胆蒽诱导的纤维肉瘤Meth A（H-2(d)）免疫小鼠产生的CD4(+) T淋巴细胞克隆受I-E(d)限制，并识别Meth A上的一种独特抗原。该抗原已被纯化并鉴定为核糖体蛋白L11。抗原表位包含在序列EYELRKHNFSDTG中，由一个单点突变导致的Asn被His（斜体）取代而产生。肿瘤包含野生型和突变等位基因。用突变表位而非野生型表位免疫BALB/cJ小鼠可保护小鼠免受随后的Meth A肉瘤攻击。将CD4(+)克隆过继转移到BALB/c小鼠中可使小鼠对Meth A肉瘤产生特异性抗性。因此，通过多个标准表明，突变的L11表位在体内是一种免疫保护性表位。
相似文献
1
The immunoprotective MHC II epitope of a chemically induced tumor harbors a unique mutation in a ribosomal protein.化学诱导肿瘤的免疫保护性MHC II表位在一种核糖体蛋白中存在独特突变。
Proc Natl Acad Sci U S A. 2001 Mar 27;98(7):3992-7. doi: 10.1073/pnas.071523398.
2
Restored immune response to an MHC-II-Restricted antigen in tumor-bearing hosts after elimination of regulatory T cells.在清除调节性T细胞后，荷瘤宿主对MHC-II限制性抗原的免疫反应得以恢复。
J Pediatr Surg. 2004 Jun;39(6):941-6; discussion 941-6. doi: 10.1016/j.jpedsurg.2004.02.049.
3
4
Peptide-specific activation of cytolytic CD4+ T lymphocytes against tumor cells bearing mutated epitopes of K-ras p21.针对携带K-ras p21突变表位的肿瘤细胞的细胞溶解性CD4+ T淋巴细胞的肽特异性激活。
Eur J Immunol. 1995 Sep;25(9):2588-97. doi: 10.1002/eji.1830250928.
5
Experimental autoimmune encephalomyelitis-resistant mice have highly encephalitogenic myelin basic protein (MBP)-specific T cell clones that recognize a MBP peptide with high affinity for MHC class II.实验性自身免疫性脑脊髓炎抗性小鼠具有高度致脑炎性的髓鞘碱性蛋白（MBP）特异性T细胞克隆，这些克隆能以高亲和力识别与MHC II类分子结合的MBP肽段。
J Immunol. 1995 Jan 1;154(1):388-98.
6
Killing of rat adenocarcinoma 13762 in situ by adoptive transfer of CD4+ anti-tumor T cells requires tumor expression of cell surface MHC class II molecules.通过CD4 +抗肿瘤T细胞的过继转移原位杀伤大鼠腺癌13762需要肿瘤细胞表面MHC II类分子的表达。
Cell Immunol. 1997 May 25;178(1):79-90. doi: 10.1006/cimm.1997.1122.
7
A unique tumor antigen produced by a single amino acid substitution.由单个氨基酸取代产生的独特肿瘤抗原。
Immunity. 1995 Jan;2(1):45-59. doi: 10.1016/1074-7613(95)90078-0.
8
Identification of overlapping epitopes in mutant ras oncogene peptides that activate CD4+ and CD8+ T cell responses.鉴定激活CD4+和CD8+ T细胞反应的突变型ras癌基因肽中的重叠表位。
Eur J Immunol. 1996 Feb;26(2):435-43. doi: 10.1002/eji.1830260225.
9
引用本文的文献
1
Shared neoantigens for cancer immunotherapy.用于癌症免疫治疗的共享新抗原。
Mol Ther Oncol. 2025 Mar 28;33(2):200978. doi: 10.1016/j.omton.2025.200978. eCollection 2025 Jun 18.
2
Brain overlapping system-level architecture influenced by external magnetic stimulation and internal gene expression in AD-spectrum patients.受外部磁刺激和AD谱系患者内部基因表达影响的大脑重叠系统级架构
Mol Psychiatry. 2025 Apr 4. doi: 10.1038/s41380-025-02991-5.
3
Cancer neoepitopes viewed through negative selection and peripheral tolerance: a new path to cancer vaccines.通过负选择和外周耐受观察到的癌症新抗原：癌症疫苗的新途径。
J Clin Invest. 2024 Mar 1;134(5):e176740. doi: 10.1172/JCI176740.
4
Relevance of mutation-derived neoantigens and non-classical antigens for anticancer therapies.突变衍生的新抗原和非经典抗原与癌症治疗的相关性。
Hum Vaccin Immunother. 2024 Dec 31;20(1):2303799. doi: 10.1080/21645515.2024.2303799. Epub 2024 Feb 12.
5
Structural and physical features that distinguish tumor-controlling from inactive cancer neoepitopes.区分肿瘤控制与非活性癌症新抗原的结构和物理特征。
Proc Natl Acad Sci U S A. 2023 Dec 19;120(51):e2312057120. doi: 10.1073/pnas.2312057120. Epub 2023 Dec 12.
6
The Resistance Mechanisms of Lung Cancer Immunotherapy.肺癌免疫治疗的耐药机制
Front Oncol. 2020 Oct 20;10:568059. doi: 10.3389/fonc.2020.568059. eCollection 2020.
7
Mass spectrometry driven exploration reveals nuances of neoepitope-driven tumor rejection.质谱驱动的探索揭示了新表位驱动的肿瘤排斥的细微差别。
JCI Insight. 2019 Jun 20;5(14):129152. doi: 10.1172/jci.insight.129152.
8
Neoepitopes of Cancers: Looking Back, Looking Ahead.癌症的新抗原：回顾与展望。
Cancer Immunol Res. 2015 Sep;3(9):969-77. doi: 10.1158/2326-6066.CIR-15-0134.
9
Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.癌症免疫学。突变图谱决定非小细胞肺癌对程序性死亡受体1（PD-1）阻断治疗的敏感性。
Science. 2015 Apr 3;348(6230):124-8. doi: 10.1126/science.aaa1348. Epub 2015 Mar 12.
10
Targeting cancer-specific mutations by T cell receptor gene therapy.通过T细胞受体基因疗法靶向癌症特异性突变。
Curr Opin Immunol. 2015 Apr;33:112-9. doi: 10.1016/j.coi.2015.02.005. Epub 2015 Feb 27.
本文引用的文献
1
Serological analysis of BALB/C methylcholanthrene sarcoma Meth A by SEREX: identification of a cancer/testis antigen.采用SEREX对BALB/C甲基胆蒽肉瘤Meth A进行血清学分析：一种癌/睾丸抗原的鉴定
Int J Cancer. 2000 Dec 15;88(6):845-51. doi: 10.1002/1097-0215(20001215)88:6<845::aid-ijc1>3.0.co;2-n.
2
Immunotherapy of human cancer: lessons from mice.人类癌症的免疫疗法：来自小鼠的经验教训。
Nat Immunol. 2000 Nov;1(5):363-6. doi: 10.1038/808795.
3
Identification of CD4+ T cell epitopes from NY-ESO-1 presented by HLA-DR molecules.从由HLA-DR分子呈递的NY-ESO-1中鉴定CD4+ T细胞表位。
J Immunol. 2000 Jul 15;165(2):1153-9. doi: 10.4049/jimmunol.165.2.1153.
4
Identification of a MHC class II-restricted human gp100 epitope using DR4-IE transgenic mice.利用DR4-IE转基因小鼠鉴定MHC II类限制性人gp100表位
J Immunol. 2000 Apr 1;164(7):3535-42. doi: 10.4049/jimmunol.164.7.3535.
5
Cloning genes encoding MHC class II-restricted antigens: mutated CDC27 as a tumor antigen.克隆编码MHC II类限制性抗原的基因：突变的CDC27作为一种肿瘤抗原。
Science. 1999 May 21;284(5418):1351-4. doi: 10.1126/science.284.5418.1351.
6
Identification of a novel major histocompatibility complex class II-restricted tumor antigen resulting from a chromosomal rearrangement recognized by CD4(+) T cells.由染色体重排产生的一种新型主要组织相容性复合体II类限制性肿瘤抗原的鉴定，该抗原可被CD4(+) T细胞识别。
J Exp Med. 1999 May 17;189(10):1659-68. doi: 10.1084/jem.189.10.1659.
7
Melanoma cells present a MAGE-3 epitope to CD4(+) cytotoxic T cells in association with histocompatibility leukocyte antigen DR11.黑色素瘤细胞将MAGE-3表位呈递给CD4(+) 细胞毒性T细胞，并与组织相容性白细胞抗原DR11相关联。
J Exp Med. 1999 Mar 1;189(5):871-6. doi: 10.1084/jem.189.5.871.
8
Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4(+) T lymphocytes.鉴定由HLA - DR分子呈递给CD4(+) T淋巴细胞的MAGE - 3表位。
J Exp Med. 1999 Mar 1;189(5):767-78. doi: 10.1084/jem.189.5.767.
9
Biochemical identification of a mutated human melanoma antigen recognized by CD4(+) T cells.一种被CD4(+) T细胞识别的突变型人类黑色素瘤抗原的生化鉴定。
J Exp Med. 1999 Mar 1;189(5):757-66. doi: 10.1084/jem.189.5.757.
10
gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand.gp100/pmel 17是一种小鼠肿瘤排斥抗原：利用高亲和力、改变的肽配体诱导“自身”反应性、杀肿瘤T细胞。
J Exp Med. 1998 Jul 20;188(2):277-86. doi: 10.1084/jem.188.2.277.
Zotero 插件